FIGURE 2.

Meta-analysis of phase II studies assessing the efficacy and safety of factor XI inhibitors compared to enoxaparin for prevention of venous thromboembolism in patients undergoing total knee arthroplasty. After combining the treatment arms of the study drug in each phase II study, factor XI inhibitors were compared to enoxaparin in a random-effects model with the amount of heterogeneity (τ²) estimated using the restricted maximum-likelihood estimator. The analysis was carried out separately for the primary efficacy endpoint, venous thromboembolism, and the primary safety endpoint, clinically relevant bleeding, with outcomes depicted as risk ratios. Tests and 95% confidence intervals (95% CI) were calculated using the Knapp and Hartung method. The quantitative synthesis was conducted using R (version 4.1.3) and the metafor package (version 3.0.2).